Open Access

Gastrointestinal involvement revealing Henoch Schonlein purpura in adults: Report of three cases and review of the literature

International Archives of Medicine20114:31

DOI: 10.1186/1755-7682-4-31

Received: 23 January 2011

Accepted: 29 September 2011

Published: 29 September 2011

Abstract

The diagnosis of Henoch-Schönlein purpura (HSP) is difficult, especially when abdominal symptoms precede cutaneous lesions.

We report three cases of adult HSP revealed by gastrointestinal (GI) involvement.

Keywords

Adult Henoch Schönlein purpura Gastrointestinal involvement

Introduction

Henoch Schonlein purpura (HSP) is a leucocytoclastic vasculitis involving small vessel with deposition of immune Ig A complexes. HSP primarily affects children, (approximately 15 cases/100.000 per year) [1]. It is less common among adults. Clinically, HSP is characterized by palpable purpura, arthritis, renal and gastrointestinal involvement. Among adults, the incidence of HSP, the clinical features and the severity seems to be different compared to children [2]. Except for potential intestinal complications, its prognosis is usually excellent. However, nephritis is another complication that might have less prognosis. We report three cases of adult-onset HSP revealed by gastrointestinal (GI) involvements.

Case reports

Over a period of 2 years (2009-2010), three patients with adult-onset HSP were admitted to Department of Internal Medicine. The clinical profiles, along with laboratory and radiological data, of the three patients are shown in Table 1. GI involvements were the first symptoms in the 3 cases. The delay between the GI involvement and the others symptoms is shown in table 1. Skin biopsy showed leucocytoclastic vasculitis with Ig A and C3 deposits in direct immunofluorescence (DIF) in the 3 cases.
Table 1

Clinical, demographic and laboratory findings of the 3 patients

Feature

Case 1

Case 2

Case 3

Age (years)/Gender

62/F

20/M

66/M

GI involvment

Hematemesis/abdominal pain

Severe abdominal pain/vomitting

Colicky abdominal pain/vomiting.

Skin rash

Lower limb and abdomen

Lower limb

Lower limb

Joints involved

Joint tenderness

Arthritis of the knee and ankles

arthritis of the ankle

Delay between GI involvement and other symptoms

3 weeks

4 weeks

2 weeks

Haemoglobin (g/dL)

10.3

15.6

14.7

Total leucocyte count (/μL)

13.000

10.400

12.200

Platelet count (/μL)

343.000

360.000

371.000

ESR (mm/1st hour)

45

22

37

Urine microscopy

Microscopc hematuria

Normal

Normal

24-hour urinary proteins

3.3 gr

Nil

Nil

Renal function

Normal

Normal

Normal

occult blood stool tests

positive

Not done

negative

Colonoscopy

colic poliposis with moderate dysplasia on the biopsy.

Not done

Not done

CT of the abdomen

Not done

Normal

Not done

Skin biopsy

Leucocytoclastic vasculitis

DIF: Ig A

Leucocytoclastic vasculitis

DIF: Ig A/C3

Leucocytoclastic vasculitis

DIF: Ig A/C3

Oesogastroduodenal endoscopy/Biopsy

Cardial ulcer with stigmata of bleeding and purpuric lesions of the bulb and the duodenum/presence of leucocytoclastic vasculitis with intestinal metaplasia and Hp gastritis

Antrite congestive with purpuric lesions of the bulb and the duodenum/presence of leucocytoclastic vasculitis with chronic and moderately active Hp antral gastritis

Purpuric lesions of the bulb and ulcers of the DI and DII portion of the bulb/erosive duodenitis and leucocytoclastic vasculitis 1

Kidney biopsy

Extracapillar glomerulonephritis with Ig A depositis in DIF

Not done

Not done

treatment

Methylprednisolone pulse (1 g/day × 3 days) + oral prednisolone associated with cyclophosphamide pulse

Colchicine®

PPI

Colchicine®

PPI

Outcome

Complete recovery

Complete recovery

Complete recovery

ESR: erythrocyte sedimentation rate; HPE: histopathology; DIF: direct immunofluorescence; GI: Gastrointestial ; PPI: proton pump inhibitors; Hp: Helicobacter pylori

Figure 1

Leucocytoclasic vasculitis of the duodenum.

The oesogastroduodenal endoscopy with biopsy showed the presence of helicobacter pylori in case 1 and 2. The rapid urease tests for Helicobacter pylori was not done.

In the first case, the colonoscopy showed the presence of colic poliposis with moderate dysplasia on the biopsy. Tumor markers (ACE, AFP, PSA, Ca-19-9) were negative. The kidney biopsy revealed "Extracapillar glomerulonephritis with Ig A depositis in DIF) and the patients received 6 monthly cyclophosphamide pulse.

Our second patient presented initially with acute appendicitis confirmed by the histological finding. There was no depositis in the DIF.

All the patients had complete recovery from their abdominal symptoms within approximately three weeks.

Discussion

HSP usually presents with a classic tetrad of rash, polyarthralgias, abdominal pain and renal disease. The clinical presentation of HSP is more severe among adult and tends to be atypical: higher rate of severe and atypical GI problems and delayed renal complications [3].

Older patients showed much more severe renal and extra-renal manifestations than younger patients in which the joint manifestations appear to be the most frequent. However, the severe GI involvements are less common in adults than children [4, 5]. The mechanism of GI involvement in HSP may include IgA deposits on small vessel wall and polymorphonuclear neutrophils (PMNs) infiltration around vessels [3].

It occurs in 50- 75% of adult patients [6].

In a recent retrospective study including 115 adults with the diagnosis of HSP, GI were found in 90 patients (78.2%). [7]; it was 24% in the study of Novak et all [8]

In a large Italian cohort of 250 patients, adults and children, with HSP, necrotic purpura was present in 96% of the cases, arthritis in 61% of the cases and GI involvement in 48% of cases. The main symptom was colicky abdominal pain. Bleeding occurred in 51% cases of GI involvement and was serious, requiring transfusion or surgery or leading to death in 11% of the cases [9].

In the retrospective study conducted by Chang and all, including 261 children with a diagnosis of HSP, 151 (58%) had abdominal pain and 46 (17.6%) had GI bleeding detected as positive stool occult blood. Seven patients had gross bloody stools [10].

When comparing 82 children and 20 adults with HSP, Uppal and all found that the frequency nausea, vomiting, malena/hematochezia and intussusception were the same in both groups. Adults had a higher frequency of diarrhea [11].

When studying 46 adults and 116 children with HSP, Blanco and all reported a higher incidence of renal (p < i0.001) and lower GI involvement at disease onset in adult HSP, but during the clinical course, GI involvement was the same in both age groups [12].

Trouiller and all tried to assess a score of severity proposed to use clinical and radiological (CT scan) severity scores to assess the usefulness and the efficacy of corticosteroid therapy. The authors conclude, by styding 34 cases of patients with HSP, 68% of them with GI involvement, that these results suggest that corticosteroids may reduce abdominal symptoms of HSP in adults with clinically severe disease [13].

In rare cases, GI involvements revealed HSP, as in our 3 patients. It was reported by Farah [14] and Moles [15]. Al Toma and all described a case of a 40- year's old man who presented with terminal ileitis complicated by thrombotic microangiopathy revealing HSP [16].

GI was the first manifestation of HSP in 11% of the patients of Trappani [17] and 8% of those of Coppo [8].

Another important retrospective study was performed by Chen and Kong including 161 patients; colicky abdominal pain was noticed in 98.1% and vomiting in 39.5% of the patients. In 25 (3%) of the reported cases, GI symptoms were manifested before skin rash [18].

The classic findings may consist in: Periumbilical colicky and abdominal pain (related to edema, bleeding), nausea, vomiting, diarrhea, constipation, abdominal distension which are usually mils and rarely severe enough to be confused with an acute abdomen leading to laparotomy. Rare GI manifestations may include: Intestinal perforation, ischemic vasculitis, intussusceptions, esophageal ulcers, pancreatitis, pseudomembranous colitis, extensive GI bloodloss requires hemodynamic monitoring, transfusion and occasionally emergent surgical intervention, appendicitis, massive bowel necrosis. Massive GI hemorrhage and grossly bloody or melanotic stools are respectively reported in 2% and 30% of the patients [13, 1922]. Simultaneous occurrence HSP and acute appendicitis is rarely observed, as in our second case [23].

Mucosal lesions develop anywhere within the GI tract. Diffuse mucosal redness, small ring-like petechiae and hemorrhagic erosions are characteristic endoscopic findings. The small intestine is considered to be the most frequently affected site. Duodenal involvement was more prominent in the second part of the duodenum than in the bulb [24].

Imaging studies consisting in abdominal X -ray film, abdominal echography, and abdominal CT, and stool occult blood tests are important examinations [10]. Laparotomy which is performed in approximately 10% is useful when esophagogastroduodenoscopy, colonoscopy and small bowel barium radiogram show normal results. Videocapsule endoscopy represents a unique improvement in the investigation of intestinal diseases, allowing an excellent visualization of the mucosa of the small bowel [25].

Malignancy also has been reported as a rare causative factor of HSP [26]. The recent retrospective study conducted by Mitsui and all found 53 cases of malignant tumors [27]. Our first patient had colic dysplasia. No previous association has been reported so far.

Helicobacter pylori (Hp) infection may be associated with the development and relapse of HSP with gastrointestinal involvement among children; Wang found that 21 of 36 HSP patients with GI manifestations were confirmed with Hp infection (58.3%). Among those patients, the relapsed patients had a Hp positive rate of 81.3% (13/16), which was significantly higher than the newly diagnosed patients (45.0%, 9/20; P < 0.05). Two of our patients had Hp infection at the moment of the diagnosis [28].

When studying 11 adult patients with HSP and 20 healthy subjects, Novak concluded that IgG antibodies to Hp may be present mostly in acute HSP, while IgA antibodies may be involved in sustaining GI symptoms underlying the chronic phase of the disease [29].

The cutaneous pathology of Hp is far from being clear, but it is speculated that the systemic effects may involve increased mucosal permeability to alimentary antigens, immunomodulation, an autoimmune mechanism or the impairment of vascular integrity [30].

Recently, polymorphism at codon 469 of the intercellular adhesion molecule-1 (ICAM-1) locus has been associated with protection against severe gastrointestinal complications in HSP [31].

In most cases, HSP spontaneously disappears without treatment. The use of corticosteroids is controversial and usually reserved for severe systemic manifestations [32].

Steroid treatment makes improvement in the GI symptoms at an early stage but does not prevent the recurrence of abdominal pain attacks. Steroids decrease the intestinal wall edema and thus the symptoms improve or disappear.

In a Randomized, Double-Blind, Placebo-Controlled Trial, including 171 patients with HSP, Prednisone was effective in reducing abdominal pain (p = 0,028); the incidence of severe abdominal pain necessitating hospital admission was greater in the placebo group than in the prednisone group [33]. These data are in keeping with those of Peru and all; these authors conclude that the steroid treatment given to HSP patients with GI manifestations might be helpful to prevent probable complications such as bleeding and intussusceptions [34].

The use of gastric acid secretion inhibitors are also very beneficial on GI involvement.

Colchicina can be used in the treatment of HSP [35, 36]. The rationale for using colchicine to treat HSP is based on the fact that colchicine perturbs microtubule function of the polymorphonuclear cell cytoskeleton [37]. This results in inhibition of polymorphonuclear cell migration to the site of inflammation.

Conclusion

GI involvements are frequent in HSP. The diagnosis is more difficult when they precede the other manifestations and especially the cutaneous rash. Treatments are still controversial.

Declarations

Authors’ Affiliations

(1)
Department of Internal Medicine, Fattouma Bourguiba Hospital
(2)
Department of Hepatogastroenterology, Fattouma Bourguiba Hospital
(3)
Departement of Anatomopathology, Fattouma Bourguiba Hospital

References

  1. Nielsen HE: Epidemiology of Schonlein-Henoch purpura. Acta Paediatr Scand 1988, 77:125–131.PubMedView ArticleGoogle Scholar
  2. Shrama A, Wanshu A, Kalra N, Singh S, Bambery P: Successful treatement of severe gastrointestinal involvement in adult- onset Henoch Schonlein Purpura. Singapore Med J Case Report 2007, 48:1047–50.Google Scholar
  3. Roberts PF, Waller TA, Brinker TM, Riffe IZ, Sayre J, Bratton RL: Henoch Schonlein purpura: A review article. Southern Med J 2007, 100:821–24.PubMedView ArticleGoogle Scholar
  4. Blazquez MR, Charlier A, Bognel JC: Manifestations digestives sévères du PR de l'adulte. Ann Gastroenterol Hepatol 1994, 30:5–8.Google Scholar
  5. Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D: Henoch-Schonlein Purpura in Adults: Outcome and Prognostic Factors. J Am Soc Nephrol 2002, 13:1271–1278.PubMedView ArticleGoogle Scholar
  6. Saulsbury FT: Cliniacal update: Henoch Schonlein purpura. Lancet 2007, 369:976–78.PubMedView ArticleGoogle Scholar
  7. Zhang Y, Huang X: Gastrointestinal involvement in Henoch-Schönlein purpura. Scand J Gastroenterol 2008, 43:1038–43.PubMedView ArticleGoogle Scholar
  8. Novák J, Márki-Zay J, Csiki Z, Sebesi J, Takáts A, Sipka S: Schönlein-Henoch purpura in adulthood (gastrointestinal manifestation and endoscopy). Z Gastroenterol 2001, 39:775–82.PubMedView ArticleGoogle Scholar
  9. Coppo R, Mazzucco G, Cagnoli L, Lupo An Schena FP: Long term prognosis of Henoch Schonlein nephritis in adult and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch Schonlein purpura. Nephrol Dial Transplant 1997, 12:2277–2283.View ArticleGoogle Scholar
  10. Chang WL, Yang YH, Lin YT, Chiang BL: Gastrointestinal manifestations in Henoch Schonlein purpura: a review of 261 patients. Acta Peadiatr 2004, 93:1427–1431.View ArticleGoogle Scholar
  11. Uppal SS, Hussain MA, Al-Raqum HA, Namppry MR, Al-Saied K, Al Assousi A, Abraham M, Malaviva AN: Henoch Schönlein's purpura in adults versus children/adolescents: A comparative study. Clin Exp Rheumatol 2006, 24:S26–30.PubMedGoogle Scholar
  12. Blanco R, Tobada Martinez VM, Garcia-Fuentes M, Gonzalez-Gay MA: Henoch Schonlein purpura in adulthood and children: Two different expressions of the same syndrome. Arthritis Rheum 1997, 40:859–64.PubMedView ArticleGoogle Scholar
  13. Trouiller S, André M, Délévaux I, Mahamadi H, Affo C: Abdominal manifestations of Henoch Schonlein purpura in adults: A retrospective study of 23 cases. Rev Med Int 2009, 30:661–70.View ArticleGoogle Scholar
  14. Farah R, Shay M: Gastrointestinal involvement in Henoch Schonlein purpura. Minerva Gastroenterol Dietol 2007, 53:295–99.PubMedGoogle Scholar
  15. Moles JR, Del Val A, Morillas J, Gaspar E, Garrigues V, Berenguer J: Gastrointestinal involvement as the first manifestation of Schoenlein-Henoch purpura. Rev Esp Enferm Dig 1991, 79:361–2.PubMedGoogle Scholar
  16. Al Toma A, Brink MA, Hagen EC: Henoch-Schönlein purpura presenting as terminal ileitis and complicated by thrombotic microangiopathy. Eur J Int Med 2005, 16:510–12.View ArticleGoogle Scholar
  17. Trapani S, Micheli A, Grisolia F, resti M, Chiappini E, Falcini F, Martino M: Henoch Schonlein Purpura in Childhood: Epidemiological and Clinical Analysis of 150 Cases Over a 5-year Period and Review of Literature. Semin Arthritis Rheumatol 2005, 35:143–53.View ArticleGoogle Scholar
  18. Chen SY, Kong MS: Gastrointestinal manifestations and complications of Henoch Schonlein purpura. Chang Gung Med 2004, 27:175–81.Google Scholar
  19. Akbar DH: Fatal complication of Henoch Schonlein purpura: Case report and literature review. Saudi J Gastroenterol 2000, 6:165–8.PubMedGoogle Scholar
  20. Ebert EC: Gastrointestinal manifestations of Henoch-Schonlein Purpura. Dis Dig Sci 2008, 53:2011–9.View ArticleGoogle Scholar
  21. Passam FH, Diamantis ID, Perisinaki G, Saridaki Z, Kritikos H, Georgopoulos D, Boumpas DT: Intestinal ischemia as the first manifestations of vasculitis. Semin Arthirtis Rheum 2004, 34:431–441.View ArticleGoogle Scholar
  22. Degushi M, Shiraki K, Itoh N: Esophageal involvement in Schonlein Henoch purpura. Gastrointestinal Endoscopy 2001, 53:241–44.View ArticleGoogle Scholar
  23. Jangjoo A, Amouzeshi A, Jalali AN: Gangrenous appendicitis in a child with Henoch-Schonlein purpura. Journal of Pediatric Surgery 2008, 43. E33-E35.Google Scholar
  24. Esaki M, Takayuki M, shotaro N, Kawasaki M, Iwai K, Hirakawa K, Tarumi KI, Yao T, Lida M: GI involvement in Henoch-Schonlein purpura. Gastrointestinal Endoscopy 2002, 56:920–23.PubMedView ArticleGoogle Scholar
  25. Stancanelli B, Vita A, Vinci M, Magnano A, Purrello F: Bleeding of small bowel in Henoch Schonlein syndrome: The successful diagnosis role of video capsule endoscopy. Am J Med 2006, 119:82–90.PubMedView ArticleGoogle Scholar
  26. Zurada JM, Ward KM, Grossman EM: Henoch Schonlein purpura associated with malignancy in adults. J Am Acad Dermatol 2006, 55:S65–70.PubMedView ArticleGoogle Scholar
  27. Mitsui H, Shibagaki N, Kawamura T, Matsue H, Shimada S: A clinical study of Henoch-Schönlein Purpura associated with malignancy. J Eur Acad Dermatol Venereol 2009, 23:394–401.PubMedView ArticleGoogle Scholar
  28. Wang BH, Zhou LQ, Zuo YH: Relationship between Helicobacter pylori infection and Henoch-Schonlein purpura with gastrointestinal involvement in children. Zhongguo Dang Dai Er Ke Za Zhi 2007, 9:367–9.PubMedGoogle Scholar
  29. Novák J, Szekanecz Z, Sebesi J, Takáts A, Demeter P, Bene L, Sipka S, Csiki Z: Elevated levels of anti-Helicobacter pylori antibodies in Henoch-Schönlein purpura. Autoimmunity 2003, 36:307–311.PubMedView ArticleGoogle Scholar
  30. Weddi B, Kappa A: Helicobacter pylori infection in skin diseases: a critical appraisal. Am J Clin Dermatol 2002, 4:273–282.View ArticleGoogle Scholar
  31. Amoli MM, Mattey DL, Calvino MC, Garcia-Porrua C, Thomson W, Hajeer AH, Ollier WE, Gonzales-Gay MA: Polymorphism at codon 469 of the intercellular adhesion molecule-1locus is associated with protection against severe gastrointestinal complications in Henoch-Schonlein purpura. J Rheumatol 2001, 28:1014–8.PubMedGoogle Scholar
  32. Yamada Y, Tanaka S, Kobayshi T, Tatsuguchi A, Sakamoto C: Gastrointestinal manifestations in Henoch-Schönlein purpura. Nippon Rinsho 2008, 66:1350–6.PubMedGoogle Scholar
  33. Ronkainen J, Koskimies O, Houhala MA, Antikainene M, Merenmies J, Rajante J, Örmala T, Turtinen J, Nuutinen M: Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr 2006, 149:241–7.PubMedView ArticleGoogle Scholar
  34. Peru H, Soylemezoglu O, Bakkaloglu SC, Elmas S, Bozkaya D, Elmaci AM, Kara F, Buyan N, Hasanoglu E: Henoch Schonlein purpura in childhood: clinical analysis of 254 cases over a 3-year period. Clin Rheumatol 2008, 27:1087–1092.PubMedView ArticleGoogle Scholar
  35. Pyne D, Mootoo R, Bhanji A: Colchicine for the treatment of recurrent Henoch-Schönlein purpura in an adult. Rheumatology (Oxford) 2001,40(12):1430–1.View ArticleGoogle Scholar
  36. Padeh S, Passwell JH: Successful treatment of chronic Henoch-Schonlein purpura with colchicine and aspirin. Isr Med Assoc J 2000,2(6):482–3.PubMedGoogle Scholar
  37. Bar-Eli M, Wilson L, Peters RS, Schwabe AD, Territo M: Microtubules in PMNs from patients with familial Mediterranean fever. Am J Med Sci 1982,284(2):2–7.PubMedView ArticleGoogle Scholar

Copyright

© Hamzaoui et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement